CAR T-cell Therapy Liso-cel Under FDA Priority Review for Relapsed or Refractory Large B-cell Lymphoma
News
The U.S. Food and Drug Administration (FDA) has agreed to review Bristol-Myers Squibb’s request to approve the investigational CAR T-cell therapy lisocabtagene maraleucel (liso-cel) for treating adults with relapsed or ... Read more